Literature DB >> 21300766

MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.

Eduardo Vilar1, Catherine M Bartnik, Stephanie L Stenzel, Leon Raskin, Jaeil Ahn, Victor Moreno, Bhramar Mukherjee, Maria D Iniesta, Meredith A Morgan, Gad Rennert, Stephen B Gruber.   

Abstract

Microsatellite instability (MSI) is displayed by approximately 15% of colorectal cancers (CRC). Defective DNA mismatch repair generates mutations at repetitive DNA sequences such as those located in the double strand break (DSB) repair gene MRE11. We assessed the mutational status of MRE11 in a panel of 17 CRC cell lines and 46 primary tumors and found a strong correlation with MSI status in both cell lines and tumors. Therefore, we hypothesized that deficiency in MRE11 may sensitize CRC cells to poly(ADP-ribose) polymerase (PARP-1) inhibition based on the concept of synthetic lethality. We further assessed the activity of the PARP-1 inhibitor, ABT-888, in CRC cell lines and observed preferential cytotoxicity in those MSI cell lines harboring mutations in MRE11 compared with both wild-type cell lines and microsatellite stable (MSS) cell lines. A significant correlation between MRE11 expression levels and cytotoxicity to ABT-888 at 10 μM was observed (R² = 0.915, P < 0.001). Using two experimental approaches, including short hairpin RNA knocking down MRE11 in the wild-type and MSS cell line SW-480 and a second cell line model transfected with mutant MRE11, we experimentally tried to confirm the role of MRE11 in conferring sensitivity to PARP-1 inhibition. Both models led to changes in proliferation in response to ABT-888 at different concentrations, and a drug-response effect was not observed, suggesting a possible contribution of additional genes. We conclude that MSI colorectal tumors deficient in DSB repair secondary to mutation in MRE11 show a higher sensitivity to PARP-1 inhibition. Further clinical investigation of PARP-1 inhibitors is warranted in MSI CRCs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21300766      PMCID: PMC3407272          DOI: 10.1158/0008-5472.CAN-10-1120

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.

Authors:  R Gryfe; H Kim; E T Hsieh; M D Aronson; E J Holowaty; S B Bull; M Redston; S Gallinger
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

Review 2.  Targeted cancer therapies based on the inhibition of DNA strand break repair.

Authors:  M J O'Connor; N M B Martin; G C M Smith
Journal:  Oncogene       Date:  2007-12-10       Impact factor: 9.867

Review 3.  DNA damage, aging, and cancer.

Authors:  Jan H J Hoeijmakers
Journal:  N Engl J Med       Date:  2009-10-08       Impact factor: 91.245

Review 4.  Microsatellite instability in colorectal cancer-the stable evidence.

Authors:  Eduardo Vilar; Stephen B Gruber
Journal:  Nat Rev Clin Oncol       Date:  2010-02-09       Impact factor: 66.675

5.  Human MRE11 is inactivated in mismatch repair-deficient cancers.

Authors:  Giuseppe Giannini; Elisabetta Ristori; Fabio Cerignoli; Christian Rinaldi; Massimo Zani; Alessandra Viel; Laura Ottini; Marco Crescenzi; Stefano Martinotti; Margherita Bignami; Luigi Frati; Isabella Screpanti; Alberto Gulino
Journal:  EMBO Rep       Date:  2002-02-15       Impact factor: 8.807

6.  Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway.

Authors:  Eduardo Vilar; Bhramar Mukherjee; Rork Kuick; Leon Raskin; David E Misek; Jeremy M G Taylor; Thomas J Giordano; Samir M Hanash; Eric R Fearon; Gad Rennert; Stephen B Gruber
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

7.  PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites.

Authors:  Jean-François Haince; Darin McDonald; Amélie Rodrigue; Ugo Déry; Jean-Yves Masson; Michael J Hendzel; Guy G Poirier
Journal:  J Biol Chem       Date:  2007-11-19       Impact factor: 5.157

8.  Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.

Authors:  Leslie A Parsels; Meredith A Morgan; Daria M Tanska; Joshua D Parsels; Brian D Palmer; R John Booth; William A Denny; Christine E Canman; Alan J Kraker; Theodore S Lawrence; Jonathan Maybaum
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

9.  Pathologic predictors of microsatellite instability in colorectal cancer.

Authors:  Joel K Greenson; Shu-Chen Huang; Casey Herron; Victor Moreno; Joseph D Bonner; Lynn P Tomsho; Ofer Ben-Izhak; Hector I Cohen; Phillip Trougouboff; Jacob Bejhar; Yanina Sova; Mila Pinchev; Gad Rennert; Stephen B Gruber
Journal:  Am J Surg Pathol       Date:  2009-01       Impact factor: 6.394

10.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

View more
  80 in total

1.  Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications.

Authors:  Frank A Sinicrope; Daniel J Sargent
Journal:  Clin Cancer Res       Date:  2012-02-02       Impact factor: 12.531

Review 2.  DNA repair dysregulation from cancer driver to therapeutic target.

Authors:  Nicola J Curtin
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

3.  Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.

Authors:  Eiji Kubota; Christopher T Williamson; Ruiqiong Ye; Anifat Elegbede; Lars Peterson; Susan P Lees-Miller; D Gwyn Bebb
Journal:  Cell Cycle       Date:  2014-05-19       Impact factor: 4.534

Review 4.  Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.

Authors:  Pavlina Spiliopoulou; Hendrik-Tobias Arkenau
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

5.  MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells.

Authors:  Glenda Nicioli da Silva; Elaine Aparecida de Camargo; André Luiz Ventura Sávio; Daisy Maria Fávero Salvadori
Journal:  Mol Biol Rep       Date:  2014-03-21       Impact factor: 2.316

6.  MicroRNA polymorphisms and risk of colorectal cancer.

Authors:  Stephanie L Schmit; Jeremy Gollub; Michael H Shapero; Shu-Chen Huang; Hedy S Rennert; Andrea Finn; Gad Rennert; Stephen B Gruber
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-23       Impact factor: 4.254

7.  DNA damage tolerance: a double-edged sword guarding the genome.

Authors:  Gargi Ghosal; Junjie Chen
Journal:  Transl Cancer Res       Date:  2013       Impact factor: 1.241

8.  The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.

Authors:  Ciric To; Eun-Hee Kim; Darlene B Royce; Charlotte R Williams; Ryan M Collins; Renee Risingsong; Michael B Sporn; Karen T Liby
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-09

9.  Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.

Authors:  Chaoyang Sun; Yong Fang; Jun Yin; Jian Chen; Zhenlin Ju; Dong Zhang; Xiaohua Chen; Christopher P Vellano; Kang Jin Jeong; Patrick Kwok-Shing Ng; Agda Karina B Eterovic; Neil H Bhola; Yiling Lu; Shannon N Westin; Jennifer R Grandis; Shiaw-Yih Lin; Kenneth L Scott; Guang Peng; Joan Brugge; Gordon B Mills
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

Review 10.  Molecular dissection of microsatellite instable colorectal cancer.

Authors:  Eduardo Vilar; Josep Tabernero
Journal:  Cancer Discov       Date:  2013-03-01       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.